- Affimed (NASDAQ:AFMD) initiated with Outperform rating and $14 (26% upside) price target by Oppenheimer.
- Prothena (NASDAQ:PRTA) initiated with Buy rating and $58 (36% upside) price target by UBS.
- ATyr Pharma (NASDAQ:LIFE) initiated with Overweight rating by JP Morgan.
- Adaptimmune (NASDAQ:ADAP) initiated with Outperform rating by Cowen & Co.
- CoLucid Pharmaceuticals (NASDAQ:CLCD) initiated with Buy rating and $15 (63% upside) price target by Stifel Nicolaus.
- Collegium Pharmaceuticals (NASDAQ:COLL) initiated with Buy rating and $20 (14% upside) price target by Jefferies.
- Fate Therapeutics (NASDAQ:FATE) initiated with Outperform rating and $10 (67% upside) price target by Leerink Swann.